Fibroblasts as a ruler of the immune microenvironment: measurement and modulation in tissue homeostasis and disease.
Fibroblasts, once considered merely passive structural components of tissues, are now recognized as dynamic regulators of the immune microenvironment.
APA
Zhang Y, Fang X, et al. (2025). Fibroblasts as a ruler of the immune microenvironment: measurement and modulation in tissue homeostasis and disease.. Frontiers in immunology, 16, 1752621. https://doi.org/10.3389/fimmu.2025.1752621
MLA
Zhang Y, et al.. "Fibroblasts as a ruler of the immune microenvironment: measurement and modulation in tissue homeostasis and disease.." Frontiers in immunology, vol. 16, 2025, pp. 1752621.
PMID
41624867
Abstract
Fibroblasts, once considered merely passive structural components of tissues, are now recognized as dynamic regulators of the immune microenvironment. Recent advances in single-cell and spatial multi-omics have revealed their profound heterogeneity, spatial organization, and functional plasticity, positioning them as a 'ruler' that measures, defines, and shapes local immune responses. In both homeostasis and disease contexts-such as cancer, autoimmune disorders, and fibrosis-distinct fibroblast subpopulations exhibit specialized roles: some drive immunosuppression via PD-L1 expression, TGF-β secretion, or metabolic reprogramming; others promote inflammation or fibrosis through cytokine and chemokine secretion; while a subset supports immune resolution and tissue repair. Spatially, fibroblasts organize immune territories by forming physical and chemical barriers, orchestrating tertiary lymphoid structures, and partitioning inflammatory zones. Their bidirectional crosstalk with immune cells-including T cells, macrophages, and B cells-further fine-tunes immune activation or suppression. The dysregulation of fibroblast subsets is a hallmark of disease progression and therapy resistance. Emerging therapeutic strategies aim to 'recalibrate' this dysfunctional ruler through targeted depletion, phenotypic reprogramming, or disruption of pathogenic signaling. Integrating fibroblast-centric metrics into clinical practice may enable precise assessment of the immune microenvironment and personalized interventions, heralding a new era in immunotherapy and fibrotic disease management.
MeSH Terms
Humans; Homeostasis; Fibroblasts; Animals; Cellular Microenvironment; Fibrosis; Autoimmune Diseases; Inflammation; Neoplasms
같은 제1저자의 인용 많은 논문 (5)
- Comment on: "Interpretable machine learning model for predicting early recurrence of pancreatic cancer: integrating intratumoral and peritumoral radiomics with body composition".
- Blocking SHP2 benefits FGFR2 inhibitor and overcomes its resistance in -amplified gastric cancer.
- Impact of contrast-enhanced computed tomography surveillance frequency on survival outcomes in patients with stage I-III colorectal cancer: A propensity score-matched retrospective cohort study.
- Corrigendum to "TMEM176A drives anti-apoptotic signaling through TGM2-mediated ERK activation in gastric cancer" [Int. Immunopharmacol. 168 (2026) 115798].
- Dietary restriction genes as modulators of breast cancer risk through metabolic pathways.